Arch Therapeutics to Provide Corporate Update at the Virtual Summer Summit
June 03, 2020 09:20 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, will be featured as a...
Arch Therapeutics Receives CE Mark Approval for AC5™ Topical Hemostat in Europe
April 13, 2020 08:15 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Topical Gel Supply Chain
March 23, 2020 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., March 23, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting on April 2, 2020
March 04, 2020 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., March 04, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Update at the 2020 LD Micro Virtual Investor Conference
March 02, 2020 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Update at Biotech Showcase™ 2020 on January 13th, 2020
January 08, 2020 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Arch Therapeutics Announces $2.5 Million Registered Direct Offering
October 17, 2019 08:00 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
UPDATE - Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
October 07, 2019 15:59 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
October 07, 2019 11:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 21st Annual Global Investment Conference
September 03, 2019 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...